Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, attention deficit hyperactivity disorder, fibromyalgia, irritable bowel syndrome, and/or premature ejaculation are described.
1. Polymorph Form B of d 9 -1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]-cyclohexanol hydrochloride (d 9 -venlafaxine hydrochloride) having the formula:
wherein:
each position designated as D has a deuterium enrichment of no less than 1% above the naturally occurring distribution of deuterium; and
said polymorph produces an X-ray powder diffraction spectrum comprising peaks at diffraction angles (2θ±5%) of 6.683, 10.201, 13.441, 15.517, 18.198, 19.719, 20.258, 21.68, 22.668, 25.543, 28.022, and 35.02.
2. The Polymorph Form B of d 9 -1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]-cyclohexanol hydrochloride (d 9 -venlafaxine hydrochloride) as recited in claim 1 , wherein said X-ray powder diffraction spectrum further comprises one or more peaks at diffraction angles (2θ±5%) of 16.64, 17.206, 23.923, 25.322, 26.502, 27.122, 27.567, 28.64, 29.241, 29.650, 31.079, 31.379, 31.978, 32.260, 32.701, 32.961, 34.12, 36.024, 36.842, 37.5, or 38.341.
3. A pharmaceutical composition comprising the compound as recited in claim 1 and one or more pharmaceutically acceptable carriers.
4. The pharmaceutical composition as recited in claim 3 , further comprising one or more release-controlling carriers.
5. The pharmaceutical composition as recited in claim 3 , further comprising one or more non-release controlling carriers.
6. The pharmaceutical composition as recited in claim 3 , wherein the composition is suitable for oral, parenteral, or intravenous infusion administration.
7. The pharmaceutical composition as recited in claim 6 , wherein the oral dosage form is a tablet or capsule.
8. The pharmaceutical composition as recited in claim 3 , wherein the compound is administered in a dose of about 0.5 milligrams to about 1,000 milligrams.
9. The pharmaceutical composition as recited in claim 3 , wherein the compound is administered in a dose of about 0.5 milligrams to about 400 milligrams.
10. The Polymorph Form B of d 9 -1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]-cyclohexanol hydrochloride (d 9 -venlafaxine hydrochloride) wherein said polymorph produces an X-ray powder diffraction spectrum substantially the same as shown in FIG. 2 .
11. The Polymorph Form B of d 9 -1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]-cyclohexanol hydrochloride (d 9 -venlafaxine hydrochloride) as recited in claim 1 , wherein each position designed as D has a deuterium enrichment of no less than 5% above the naturally occurring distribution of deuterium.
12. The Polymorph Form B of d 9 -1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]-cyclohexanol hydrochloride (d 9 -venlafaxine hydrochloride) as recited in claim 1 , wherein each position designed as D has a deuterium enrichment of no less than 10% above the naturally occurring distribution of deuterium.
13. The Polymorph Form B of d 9 -1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]-cyclohexanol hydrochloride (d 9 -venlafaxine hydrochloride) as recited in claim 1 , wherein each position designed as D has a deuterium enrichment of no less than 20% above the naturally occurring distribution of deuterium.
14. The Polymorph Form B of d 9 -1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]-cyclohexanol hydrochloride (d 9 -venlafaxine hydrochloride) as recited in claim 1 , wherein each position designed as D has a deuterium enrichment of no less than 50% above the naturally occurring distribution of deuterium.
15. The Polymorph Form B of d 9 -1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]-cyclohexanol hydrochloride (d 9 -venlafaxine hydrochloride) as recited in claim 1 , wherein each position designed as D has a deuterium enrichment of no less than 70% above the naturally occurring distribution of deuterium.
16. The Polymorph Form B of d 9 -1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]-cyclohexanol hydrochloride (d 9 -venlafaxine hydrochloride) as recited in claim 1 , wherein each position designed as D has a deuterium enrichment of no less than 80% above the naturally occurring distribution of deuterium.
17. The Polymorph Form B of d 9 -1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]-cyclohexanol hydrochloride (d 9 -venlafaxine hydrochloride) as recited in claim 1 , wherein each position designed as D has a deuterium enrichment of no less than 90% above the naturally occurring distribution of deuterium.
18. The Polymorph Form B of d 9 -1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]-cyclohexanol hydrochloride (d 9 -venlafaxine hydrochloride) as recited in claim 1 , wherein each position designed as D has a deuterium enrichment of no less than 98% above the naturally occurring distribution of deuterium.
19. The Polymorph Form B of d 9 -1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]-cyclohexanol hydrochloride (d 9 -venlafaxine hydrochloride) of claim 1 , which further produces a solid state infrared spectrum comprising peaks at about 3319 and 2917 cm −1 .
20. The Polymorph Form B of d 9 -1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]-cyclohexanol hydrochloride (d 9 -venlafaxine hydrochloride) of claim 1 , wherein:
each position designed as D has a deuterium enrichment of no less than 90% above the naturally occurring distribution of deuterium; and
said polymorph produces:
(i) an X-ray powder diffraction spectrum comprising at least four peaks at diffraction angles (2θ) of 6.683, 10.201, 13.441, 15.014, 15.517, 16.84, 17.206, 18.198, 19.179, 20.258, 21.68, 22.668, 23.923, 25.322, 25.543, 26.502, 27.122, 27.567, 28.022, 28.64, 29.241, 29.650, 31.079, 31.379, 31.978, 32.260, 32.701, 32.961, 34.12, 35.02, 36.024, 36.842, 37.5, or 38.341 2θ; and
(ii) a solid state infrared spectrum comprising peaks at about 3319 and 2917 cm −1 .